Stasis in Medical Technology

Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers

...ion from this study is also expected to support Cardium and TRC advancing into other important product opportunities including pressure ulcers, venous stasis ulcers, bone injury repair and potentially other advanced therapeutic applications." About Cardium Cardium Therapeutics, Inc. and its su...

ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009

...ollowing wound bed preparation. For all four patients, the time to healing was between one and four weeks and one patient's ulcer had been present in stasis for 24 weeks prior to Altrazeal(TM) treatment. Commenting on the results, Dr. Persich stated "Altrazeal(TM) represents a new generation of smart dres...

Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers

...vention, diabetes now affects nearly 24 million people in the United States alone," states Cathy Bradshaw, President of Wound Care Innovations. Venous stasis ulcers of the lower extremity is a common problem among diabetic patients and presents significant quality of life issues for them as well as tremendo...

Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations

...D is comprised almost entirely of purified type-I collagen protein and is clinically indicated in the US for the management of pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, partial and full thickness wounds, and superficial injuries. Unlike alginates, hydrogels and h...